Real-World data shows triple inhaler eases COPD symptoms
NCT ID NCT06712563
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study pools data from multiple countries to see how a triple-combination inhaler (BGF) affects the daily lives of 2,000 people with moderate to severe COPD. Researchers will compare health status scores at 1, 3, and 12 months after starting treatment. The goal is to understand real-world benefits, not to test a new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Mississauga, Canada
-
Research Site
Hamburg, Germany
-
Research Site
Athens, Greece
-
Research Site
Milan, Italy
-
Research Site
Tokyo, Japan
-
Research Site
Bucharest, Romania
-
Research Site
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection ease COPD and cut Flare-Ups?
- Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD
- Double-Duty inhaler aims to ease breathing in COPD
- Could AI help pharmacists give better advice?
- New COPD drug tested across chinese, japanese, and european volunteers
- New digital tool aims to simplify care for seniors with multiple conditions